Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
15.50
+0.29 (1.91%)
At close: Feb 27, 2026, 4:00 PM EST
15.77
+0.27 (1.74%)
After-hours: Feb 27, 2026, 7:47 PM EST
Cullinan Therapeutics Market Cap
Cullinan Therapeutics has a market cap or net worth of $915.68 million as of February 27, 2026. Its market cap has increased by 59.01% in one year.
Market Cap
915.68M
Enterprise Value
584.27M
1-Year Change
59.01%
Ranking
Category
Stock Price
$15.50
Market Cap Chart
Since the IPO on January 8, 2021, Cullinan Therapeutics's market cap has increased from $829.45M to $915.68M, an increase of 10.40%. That is a compound annual growth rate of 1.94%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 27, 2026 | 915.68M | 49.76% |
| Dec 31, 2025 | 611.44M | -13.79% |
| Dec 31, 2024 | 709.21M | 62.69% |
| Dec 29, 2023 | 435.93M | -9.73% |
| Dec 30, 2022 | 482.90M | -28.36% |
| Dec 31, 2021 | 674.05M | -18.74% |
| Jan 8, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| uniQure | 973.62M |
| Valneva SE | 971.11M |
| ArriVent BioPharma | 948.23M |
| Xencor | 936.53M |
| SpyGlass Pharma | 932.89M |
| Theravance Biopharma | 924.77M |
| GH Research | 921.14M |
| ARS Pharmaceuticals | 917.32M |